Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects

Robert Kügler,*1 Andrea Mietens,*1 Mathias Seidensticker,*1 Sabine Tasch,* Florian M. Wagenlehner,‡ Andre Kaschtanow,* Yudy Tjahjono,* Claudia U. Tomczyk,* Daniela Beyer,* Gail P. Risbridger,‡ Betty Exintaris,§ Stuart J. Ellem,* and Ralf Middendorff*‡  
*Institute of Anatomy and Cell Biology and 1Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig-University Giessen, Giessen, Germany; 2Department of Anatomy and Developmental Biology, Monash University, Melbourne, Victoria, Australia; and 3Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia

ABSTRACT: Prostate carcinoma and benign prostate hyperplasia (BPH) with associated lower urinary tract symptoms (LUTS) are among the most prevalent and clinically relevant diseases in men. BPH is characterized by an enlargement of prostate tissue associated with increased tone of smooth muscle cells (SMCs) which surround the single glands composing the prostate. Secretions of the glands leave the prostate through local excretory ducts during the emission phase of ejaculation. Pharmacological treatment of BPH suggests different local drug targets based on reduction of prostate smooth muscle tone as the main effect and disturbed ejaculation as a common side effect. This highlights the need for detailed investigation of single prostate glands and ducts. We combined structural and functional imaging techniques—notably, clear lipid-exchanged, acrylamide-hybridized rigid imaging/immunos- 


KEY WORDS: contractility · time-lapse imaging · 3D imaging · PDE5 inhibitors

Benign prostatic hyperplasia (BPH) is a highly prevalent, nonmalignant disease that affects aging men and results in serious lower urinary tract symptoms (LUTS) (1). Morphologically, BPH is mainly characterized by an increase in interstitial stroma, leading to an increase in prostate size. In the human prostate, smooth muscle cells (SMCs) are an important component of the interstitial stroma among the glands. Blood vessels and the prostate excretory ducts are additional prostate structures that are characterized by copious amounts of SMCs (2–4). The ducts function to transport secretions from individual glands of the prostate, which are responsible for one-third of the ejaculate (5), toward the urethra and are of particular importance for the emission phase of ejaculation. Most of the drugs used for the treatment of LUTS and BPH target SMC function (6). α1-Adrenergic blockers (e.g., tamsulosin and silodosin) are well-established drugs for BPH treatment (7, 8), but are associated with significant
side effects such as ejaculation disorders (9–11). Phosphodiesterase (PDE)-5 inhibitors (e.g., tadalafil) are promising new therapeutic options for the treatment of BPH (12–17). PDE5 hydrolyzes the second messenger cGMP, which is produced by binding of NO and natriuretic peptides to specific guanylyl cyclases (18). PDEs essentially regulate the duration of cGMP action (19). In their most recent review, Gacci et al. (20) describe a series of cGMP/PDE5 actions in LUTS and BPH such as modulation of oxygenation, inflammation, proliferation, and nerve activity. However, the most established mechanism of action of PDE5 inhibitors is smooth muscle relaxation leading to reduced muscle tone (20, 21). PDE5 inhibitors have been shown to relax isolated prostate strips in numerous species (14, 21–23).

Information on the spatial arrangement of the SMCs and PDE5-expressing cells in the stromal compartment is scarce, whereas direct visualization and demonstration of the effects of PDE5 inhibition has not been shown. Moreover, knowledge about PDE5 expression in the ducts and their susceptibility to PDE5 inhibitors is completely lacking. These data are of particular importance, especially since a characteristic adverse side effect of other BPH therapeutics, such as α1-adrenergic blockers, is abnormal and decreased ejaculation (24, 25). In this study, we used novel imaging techniques to examine the effects of PDE5 inhibitors on the different muscular structures of the prostate, including those involved in ejaculation.

MATERIALS AND METHODS

Tissues

Human tissue samples originated from patients (age range, 60–79 yr; median, 71.7 ± 9.5) undergoing transurethral monopolar electroresection of the prostate for BPH or radical prostatectomy for prostate cancer. Use of human prostate tissue was approved by the ethics committee of the Medical Faculty, Justus-Liebig-University Giessen, Germany (ethical vote 49/05, 2005), and all patients gave written informed consent.

Rat prostate tissue was obtained from adult Wistar rats housed in the animal facility of Justus-Liebig-University Giessen. Housing, animal care and all procedures were conducted according to the guidelines for animal care and approved by the committee for laboratory animals of Justus-Liebig-University Giessen (JLU no. 469_M and 510_M).

Tissues were fixed in 4% paraformaldehyde for 24 h at 4°C. Prostate tissue was incubated in hydrogel-forming solution [acrylamide 4% in PBS, bis-acrylamide 0.05% in PBS and 0.25% 2,2′-azobis(2-methylpropionamide) dihydrochloride] for 24 h at 4°C followed by polymerization at 37°C for 3 h. Tissue sections were fixed in 4% paraformaldehyde for 24 h at 4°C. Prostate tissue was incubated in hydrogel-forming solution [acrylamide 4% in PBS, bis-acrylamide 0.05% in PBS and 0.25% 2,2′-azobis(2-methylpropionamide) dihydrochloride] for 24 h at 4°C followed by polymerization at 37°C for 3 h. Tissue sections were cleared in a solution containing SDS 10% and boric acid 200 mM (pH 7.4) in water, for at least 5 d. Excessive washing steps with PBS-Triton 0.1% were performed before and after adding primary antibodies. Primary and secondary antibodies were the same as mentioned above (see immunostaining), but at dilutions of 1:100 and 1:200, respectively. Antibodies were diluted in PBS-Triton 0.1% and incubated for at least 5 d at room temperature. After further washing steps (24 h), tissue was transferred into a refractory index-matching buffer: Histodenz 88% (D2158; Millipore-Sigma, St. Louis, MO, USA), rabbit polyclonal anti–PDE5 (1:1000; generous gift from Laurinda Jaffe, University of Connecticut Health Center, Farmington, CT, USA) and Alexa Fluor 488 anti-rabbit IgG (1:500; Jackson ImmunoResearch, West Grove, PA, USA) and Alexa Fluor 555 anti-mouse IgG (1:500; Thermo Fisher Scientific, Waltham, MA, USA).

Immunostaining

For immunofluorescence staining of paraffin sections we used monoclonal mouse anti-α-smooth muscle actin (SMA,1:1000; Millipore-Sigma, St. Louis, MO, USA), rabbit polyclonal anti–PDE5 (1:1000; generous gift from Laurinda Jaffe, University of Connecticut Health Center, Farmington, CT, USA) and the fluorescence-labeled secondary antibodies Cy3 anti-mouse IgG (1:500; Jackson ImmunoResearch, West Grove, PA, USA) and Alexa Fluor 488 anti-rabbit IgG (1:500; Thermo Fisher Scientific, Waltham, MA, USA).

Clear lipid-exchanged acrylamide-hybridized rigid imaging/immunostaining/in situ hybridization-compatible tissue-hydrogel

Clear lipid-exchanged acrylamide-hybridized rigid imaging/immunostaining/in situ hybridization-compatible tissue-hydrogel (CLARITY) (28) is a spatial advancement of common histochemical techniques and allows generating a 3-dimensional image of whole tissues. It offers the possibility of transforming intact biologic tissue into a translucent hydrogel-tissue hybrid by removing lipid components responsible for light scattering and thus tissue opacity. In this form, the hybrid is permeable to agents such as specific antibodies, and imaging against a translucent background can be greatly enhanced.

Patient tissue samples and rat tissue of ~1 mm³ were treated as described by Yang et al. (29) with a few modifications (30). Tissue sections were fixed in 4% paraformaldehyde for 24 h at 4°C. Prostate tissue was incubated in hydrogel-forming solution [acrylamide 4% in PBS, bis-acrylamide 0.05% in PBS and 0.25% 2,2′-azobis(2-methylpropionamide) dihydrochloride] for 24 h at 4°C followed by polymerization at 37°C for 3 h. Tissue sections were cleared in a solution containing SDS 10% and boric acid 200 mM (pH 7.4) in water, for at least 5 d. Excessive washing steps with PBS-Triton 0.1% were performed before and after adding primary antibodies. Primary and secondary antibodies were the same as mentioned above (see immunostaining), but at dilutions of 1:100 and 1:200, respectively. Antibodies were diluted in PBS-Triton 0.1% and incubated for at least 5 d at room temperature. After further washing steps (24 h), tissue was transferred into a refractory index-matching buffer: Histodenz 88% (D2158; Millipore-Sigma) in 0.02% sodium azide (pH 7.5) for 24 h at room temperature. Documentation was performed on an LSM 710 Confocal Laser Scanning Microscope (Zeiss, Jena, Germany), Z-stacks were captured every 1.5–5 μm and reconstructed in Imaris by using the command “3D projects,” allowing interpolation and contrast autoenhancement if necessary.
Statistical analysis

Only vital samples (confirmed by a visible response to noradrenaline) were included. Normal distribution of the data was checked by the Kolmogorov-Smirnov test. Contraction frequencies were analyzed by paired 1-tailed t tests for normally distributed data; otherwise, the Mann-Whitney U test was applied. For noradrenaline effects in the ducts, assessed as areas before and after treatment, paired 2-tailed t tests were used. All statistical procedures were performed with GraphPad Prism software (version 4.03; GraphPad Software, La Jolla, CA, USA).

RESULTS

All SMC compartments of the prostate show PDE5 expression

Prostate tissue comprises glands and their ducts (Fig. 1A, B) which transport glandular secretions toward the urethra. Both are encompassed by interstitial tissue including also blood vessels (Fig. 1A). In the human prostate, SMCs (marked by SMA immunostaining) are found, not only in the interstitial tissue around prostate glands (Fig. 1C, F) and in blood vessels (Fig. 1H), but also in the ducts (Fig. 1J, L, M). Bigger ducts (Fig. 1J, L) are distinguished by several SMC layers surrounding the epithelial layer (Fig. 1J, L, M). In our efforts to reveal the prostate targets of drugs used for BPH treatment, we localized PDE5, the enzyme affected by PDE5 inhibition. PDE5 immunoreactivity was regularly observed in interstitial SMCs, confirmed by double staining of SMA and PDE5 (Fig. 1C–E). CLARITY visualized the 3-dimensional arrangement of PDE5-expressing SMCs thereby providing a better understanding of the spatial architecture of these cells which fill the interstitial compartments and are oriented in various directions (Fig. 1F, G and Supplemental Movies 1 and 2). PDE5 is also expressed in vascular SMCs (Fig. 1H, I) and in the SMCs of the larger (Fig. 1J–L) and smaller (Fig. 1M) prostatic ducts.

Relaxing effects of PDE5 inhibition can be directly visualized in human prostate

Time-lapse imaging of human prostate tissue was performed to directly visualize contractions of interstitial SMCs in their regular environment and to monitor effects of PDE5 inhibition. Slow spontaneous contractions of the tissue were readily observed. The PDE5 inhibitor sildenafil markedly reduced spontaneous contractile frequency (Fig. 2A and Supplemental Movie 3). Further treatment with noradrenaline confirmed functional integrity and viability of the tissue sample. Figure 2C gives a visual impression of contractions and sildenafil effects; in this example, sildenafil even abolished spontaneous contractions. Statistical analysis showed that PDE5 inhibition by sildenafil significantly reduced spontaneous contractile frequency (Fig. 2D). After time-lapse imaging, histologic evaluation of the tissue showed SMCs oriented in the various directions in the interstitial compartment around glandular tissue (Fig. 2B).

Isolated prostate glands show spontaneous contractions that are inhibited by PDE5 inhibition

Our CLARITY approach 3-dimensionally demonstrated that the interstitial periglandular SMCs in rat prostate (Fig. 3A and Supplemental Movie 4) were arranged tighter around the glands, than in the human prostate, where SMCs were widely dispersed in the interstitium (see Fig. 1F and Supplemental Movie 1). This structural difference enabled visualization and analysis of the contractile pattern of single, isolated glands with their musculature. Movies revealed spontaneous contractility occurring in a slightly irregular pattern (Fig. 3B and Supplemental Movie 5). Following wall movements through the time stack at the indicated position (Fig. 3B), the contractile pattern and the drug effects were analyzed (Fig. 3C). Addition of sildenafil resulted in a clearly visible (Fig. 3B, C and Supplemental Movie 5) and significant (Fig. 3D) reduction of contractile frequency. The response to noradrenaline confirmed viability of the tissue (not displayed). Analogous experiments were performed using the PDE5 inhibitor tadalafil. Our findings showed a reduction of spontaneous contractile frequency in rat prostate glands by tadalafil (Fig. 3E), as seen before by sildenafil.

In line with our functional studies PDE5 was found in SMCs surrounding rat prostate glands, as indicated by SMA and PDE5 double staining (Fig. 3F, G). Corresponding to the human tissue (Fig. 1) PDE5 was also found in SMCs of blood vessels (Fig. 3F–K and Supplemental Movie 6) and prostate ducts (Fig. 3I–K). Interestingly, the composition of prostate ducts in rat (Fig. 3I) and human (Fig. 1J) and their PDE5 expression in surrounding SMCs (Fig. 3I–K vs. Fig. 1J–M) is comparable.

Prostate ducts do not contract spontaneously. Contractions induced by noradrenaline, mediating emission and ejaculation, are not disturbed by PDE5 inhibition.

Whereas the role of PDE5 inhibitors in vasculature has already been discussed (20), nothing is known about the functional relevance of PDE5 inhibitors in prostate ducts with their large amount of PDE5-expressing SMCs. Therefore, prostate ducts were isolated and investigated by our life-imaging approach ex vivo (Fig. 4A). As can be seen in Supplemental Movie 7 and the corresponding time stack analyses (Fig. 4B) the duct did not show (spontaneous) contractions without treatment, which contrasts with the regular observation of spontaneous contractility in glands (see Figs. 2 and 3). No obvious sildenafil effect was visible in the duct samples—in particular, no dilatation was seen. Noradrenaline, however, when used to test the viability of the tissue and to mimic sympathetic stimulation of the prostate during ejaculation, resulted in a rapid and strong contraction of the whole duct (Fig. 4B and Supplemental Movie 7), also illustrated by a distinct area change (Fig. 4D). Spillage of secretions from the duct during the noradrenaline-induced contraction was also noted (Supplemental Movie 7). In contrast, the glands
Figure 1. Localization of PDE5 in SMCs of glands, vessels, and ducts of the human prostate. A, B) Preparation of glandular structures of the prostate showed glands (g) and ducts (d) to be the components of the secretory and transport system in addition to vessels (v) as part of the interstitial tissue. SMC localization of PDE5 in human prostate. C–G) PDE5 in human interstitial SMCs. In the human prostate, interstitial SMCs were identified by SMA expression in the stromal compartment (*) around the glands (g). PDE5 expression was colocalized to these SMA-positive cells, as shown in the merged image. E) DAPI staining helped to identify the location of the epithelium. F, G) Movie frame shots from double staining of SMA and PDE5 in the human prostate using a 3-dimensional CLARITY approach showed congruent localization of both antigens. Please refer to the corresponding Supplemental Movies 1 and 2 to appreciate the spatial architecture. H, I) PDE5 in human vascular SMCs. Immunostaining with SMA and PDE5 confirmed an equal distribution in vascular (v) contractile cells in human prostate, stromal interstitial cells are (continued on next page)
contracted only slightly, and no relevant area change was visible.

The PDE5 inhibitors used to treat BPH interfered with the prostatic component of ejaculation. We therefore investigated systematically whether (pre)treatment of the prostate duct with sildenafil changes the contractile response to noradrenaline, the key player for the initiation of ejaculation. For this, we cut prostate ducts in two parts (Fig. 4C). Each duct served as its own control (Fig. 4C) and was exposed to sildenafil (+Sild.) or vehicle (−Sild.). To assess and quantify noradrenaline-induced contractions, we used frame shots from movies before and after the addition of noradrenaline and compared the area occupied by the tissue as a surrogate parameter for the contraction (Fig. 4D). To confirm that the samples used in the contraction assay were correctly classified as prostate ducts, we used Azan-stained histologic sections (Fig. 4E) and found the typical architecture of prostate ducts consisting of several smooth muscle layers around the epithelium. Noradrenaline-induced contractions of the isolated duct segments occurred irrespective of sildenafil pretreatment and in both cases, the area after noradrenaline treatment was ~80%, compared with the area before treatment (Fig. 4F). Sildenafil did not significantly delay the time from addition of the drug to onset of contractions; rather, a prompt reaction was seen (Fig. 4G).

**DISCUSSION**

In the present study, we combined structural and functional imaging of intact prostate tissue to characterize SMC compartments and their function within the prostate. Our approach using isolated prostate glands and ducts largely maintains tissue architecture and allows assessment of pharmacologic effects. It is therefore suitable for systematic testing of drugs assumed to affect prostate function or

**Figure 2.** Visualization of spontaneous contractility of human prostate tissue sensitive to PDE5 inhibition. A) Frame shot from Supplemental Movie 3 shows a piece of human prostate tissue by transillumination imaging and indicates the location of the virtual slice (blue line) which is followed through the time stack in C. Scale bar, 75 μm. B) Azan staining of one 6 μm section from the tissue used in (A). Interstitial SMCs stained red. Scale bar, 75 μm. C) Contractions elicited small movements of the human prostate tissue and became visible as little twitches (marked by vertical arrows for better visibility). Slow, spontaneous, irregular contractions are visible, and their frequency is reduced (or even abolished in this example) after the addition of the PDE5 inhibitor sildenafil. D) Statistical analysis of 6 human samples showed a significant reduction of spontaneous contractile frequency by sildenafil. *P ≤ 0.05.
the prostatic component of the emission phase of ejaculation. Beside the vessels, we discriminated distinct SMC compartments in glands and ducts with different spatial architecture, function, and pharmacologic response to PDE5 inhibition. In prostate ducts which were characterized by high amounts of PDE5-expressing SMCs we directly uncovered the absence of spontaneous contractions and ensuing lack of sildenafil effects. Interestingly, data also showed that noradrenaline-induced contractions of prostatic ducts, as found during ejaculation, remain unaltered in the presence of sildenafil treatment.

Prostate ducts lacked spontaneous contractions, whereas isolated prostate glands exhibited spontaneous contractile activity. These contractions may provide a basal muscular tone and could be important for agitation of secretions in the glandular lumen. This finding supports the idea of pacemaker cells which generate contractile activity, suggested in human and guinea pig
prostate cells, independent of neuronal activation (31). Because noradrenaline effects on glandular acini were relatively weak, contractions of the secretory system (glands) may be of limited importance in the context of ejaculation physiology, different from the transport system (excretory ducts). Periglandular SMCs were shown to express PDE5, and the addition of sildenafil or tadalafil resulted in diminished contractile frequency. It would be interesting to know whether long-term treatment with PDE5 inhibitors results in an increasing number of prostatic concretions, caused by reduced agitation of secretions. Currently, long-term experience with PDE5 inhibitors in men with LUTS is limited to one trial with tadalafil with only a 1 yr follow-up (32).

Because of the different architecture of interstitial SMCs in the prostate, functionally intact glands can be isolated only in rodents. Intact human tissue pieces and isolated rat glands showed spontaneous contractility in a slightly irregular pattern at a similar range of frequencies, and reactions to drugs like sildenafil and noradrenaline are comparable. Our data suggest that in human stromal tissue (with its high amounts of SMCs around glandular structures), the physiologic role of spontaneous contractions may also be associated with glandular function.

Prostate ducts may be seen as a conduit serving to expel secretions during ejaculation which is highlighted by our finding of powerful contractions observed upon noradrenaline exposure, whereas in unstimulated conditions, no spontaneous contractile activity was detected. To our knowledge, this study is the first to investigate the effects of a PDE5 inhibitor on prostate ducts. PDE5 inhibitors did not affect noradrenaline-induced contractions that mediate ejaculation. Thus, PDE5 inhibitor-induced disturbances of prostate secretion during ejaculation are unlikely. This finding is of clinical relevance, given that drugs alternatively used for the treatment of BPH such as $\alpha_1$-adrenergic blockers are known to negatively affect ejaculation (24, 25). Whereas $\alpha_1$-adrenergic receptor inhibitors and ejaculation-mediating noradrenaline bind to the same membrane receptor (33), PDE5 inhibitors do not;
they inhibit hydrolysis of intracellular cGMP by PDE5 (34). The insensitivity to PDE5 inhibitors in the ducts cannot be explained by missing PDE5 in these structures, as PDE5 was readily detected in SMCs of prostate ducts from both human and rat. However, the precise role of PDE5 in prostate ducts is not clear. It is plausible that (basal) PDE5 activity limits cGMP levels and thus reduces SMC relaxation. Thereby a basic tension of the duct musculature may be maintained to ensure the rapid catecholamine-induced contractions that are necessary for ejaculation.

In comparison to sole analyses of ejaculation and ejaculate, our data give much more information about the physiology of the prostatic component of ejaculation. Different from organ bath studies with strips of the whole prostate (14, 21–23), our methodology allows discrimination between effects on SMCs of the ducts and the interstitial periglandular compartment.

The CLARITY approach (28, 30) added the third dimension to the usual histologic techniques and valuable information to our understanding of the spatial arrangement and function of SMCs around the prostate glands. In human prostate, SMCs not only surrounded the epithelial layer of the glands, but were detectable in all parts of the interstitial compartment with different orientation. In the rat, the 3-dimensional projection of the SMCs showed a bandage-like arrangement around the glands, with regions devoid of SMCs consistent with the observation of “patchy” contractile activity in our functional studies.

Besides PDE5 [see Gacci et al. (20)], other components of cGMP pathways now represent potential targets for therapeutic intervention. These include other PDEs (35), as well as cGMP-generating guanylyl cyclases (23, 36, 37). In all cases, the beneficial cGMP effect for patients with BPH may be the reduction of muscular tone in the pathologically enlarged interstitial compartment, along with the maintenance of the noradrenaline-induced contractile function in the ducts.

In summary, our study advances our understanding of different SMC compartments in the prostate with respect to their distinct spatial arrangement, physiologic function, and pharmacologic responses.

ACKNOWLEDGMENTS

The authors thank Dr. Laurinda Jaffe (University of Connecticut Health Center, Farmington, CT), for providing us with anti-PDE5 antibodies; Dr. Dieter Müller (Justus-Liebig-University Giessen, Germany), for helpful discussions; and Ingrid Schneider-Hüther, Tanja Bloch, and Kerstin Wilhelm (Justus-Liebig-University), for excellent technical assistance. Funding was provided by the Deutsche Forschungsgemeinschaft Grant GRK 1871 and funding from Monash University, Australia, to the International Research Training Group (IRTG), a collaboration between Justus-Liebig-University Giessen and Monash University. The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

R. Kügler, M. Seidensticker, and S. Tasch performed the experiments; A. Kaschtanow and C. U. Tomczyk performed the CLARITY imaging; R. Kügler, A. Mieten, M. Seidensticker, and D. Beyer contributed to the statistical analyses; F. M. Wagenlehner provided material support; F. M. Wagenlehner, Y. Tajbiono, G. P. Risbridger, B. Exintaris, and S. Ellem contributed valuable advice to the redaction of the manuscript; R. Kügler, A. Mieten, and R. Middendorff wrote the manuscript; and R. Middendorff designed the study and directed the project.

REFERENCES


Received for publication June 18, 2017. Accepted for publication October 16, 2017.